Join Growin Stock Community!

Pulmatrix, inc.PULM.US Overview

US StockHealthcare
(No presentation for PULM)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PULM AI Insights

PULM Overall Performance

PULM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PULM Recent Performance

-35.45%

Pulmatrix, inc.

0.05%

Avg of Sector

-0.31%

S&P500

PULM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PULM Key Information

PULM Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PULM Profile

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Price of PULM

PULM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PULM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3640.11
PB Ratio
2.40
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-207333.33%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3640.11
PB Ratio
2.40
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-207333.33%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is PULM's latest earnings report released?

    The most recent financial report for Pulmatrix, inc. (PULM) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PULM's short-term business performance and financial health. For the latest updates on PULM's earnings releases, visit this page regularly.

  • How is PULM's revenue growth?

    In the latest financial report, Pulmatrix, inc. (PULM) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does PULM have?

    At the end of the period, Pulmatrix, inc. (PULM) held Total Cash and Cash Equivalents of 4.09M, accounting for 0.99 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PULM's EPS continuing to grow?

    According to the past four quarterly reports, Pulmatrix, inc. (PULM)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.25. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PULM?

    Pulmatrix, inc. (PULM)'s Free Cash Flow (FCF) for the period is -706K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 44.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.